UA95287C2 - Rosuvastatin zinc salt - Google Patents

Rosuvastatin zinc salt

Info

Publication number
UA95287C2
UA95287C2 UAA200813120A UAA200813120A UA95287C2 UA 95287 C2 UA95287 C2 UA 95287C2 UA A200813120 A UAA200813120 A UA A200813120A UA A200813120 A UAA200813120 A UA A200813120A UA 95287 C2 UA95287 C2 UA 95287C2
Authority
UA
Ukraine
Prior art keywords
zinc salt
rosuvastatin zinc
rosuvastatin
zinc
salt
Prior art date
Application number
UAA200813120A
Other languages
English (en)
Ukrainian (uk)
Inventor
Поль Ваго
Дьюла Симиг
Дьйордь Клементис
Петер Томпе
Сандорне Тапаи
Original Assignee
Эгиш Дьйодьсердьяр Нильваношан Мюкьодо Ресвеньтаршашаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эгиш Дьйодьсердьяр Нильваношан Мюкьодо Ресвеньтаршашаг filed Critical Эгиш Дьйодьсердьяр Нильваношан Мюкьодо Ресвеньтаршашаг
Publication of UA95287C2 publication Critical patent/UA95287C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Данное изобретение касается цинковой соли розувастатина формулы (I), способа получения и лекарственных препаратов, содержащих указанную соль.Цинковую соль розувастатина согласно данному изобретению получают путем взаимодействия розувастатина с алкоголятом цинка, энолятом цинка или неорганической или органической солью цинка и выделением полученной таким образом цинковой соли розувастатина (2:1).(I)
UAA200813120A 2006-04-13 2007-04-12 Rosuvastatin zinc salt UA95287C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0600293A HU227696B1 (en) 2006-04-13 2006-04-13 Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it

Publications (1)

Publication Number Publication Date
UA95287C2 true UA95287C2 (en) 2011-07-25

Family

ID=89986710

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200813120A UA95287C2 (en) 2006-04-13 2007-04-12 Rosuvastatin zinc salt

Country Status (12)

Country Link
US (1) US9174945B2 (ru)
EP (1) EP2013188B1 (ru)
JP (1) JP5439168B2 (ru)
KR (1) KR20080109088A (ru)
CN (1) CN101490015B (ru)
CA (1) CA2649219C (ru)
EA (1) EA016141B1 (ru)
ES (1) ES2605579T3 (ru)
HU (1) HU227696B1 (ru)
IL (1) IL194674A (ru)
UA (1) UA95287C2 (ru)
WO (1) WO2007119085A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1005147A2 (pt) * 2009-01-15 2019-09-24 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag processo de preparação de sais de rosuvastatina
HUP0900285A2 (en) 2009-05-07 2011-01-28 Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag Rosuvastatin salts and preparation thereof
HUE029858T2 (en) * 2009-07-24 2017-04-28 Egyt Gyogyszervegyeszeti Gyar Crystalline Form I of Rosuvastatin Zinc salt
HU230737B1 (hu) 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
HU229260B1 (en) 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
HU230987B1 (hu) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
CN102357096A (zh) * 2011-09-09 2012-02-22 北京阜康仁生物制药科技有限公司 一种含有他汀类药物锌盐的降血脂组合物
CN102558016A (zh) * 2012-02-14 2012-07-11 北京阜康仁生物制药科技有限公司 一种新型具有高度降脂活性的化合物及其制备方法
HU231036B1 (hu) * 2013-09-30 2019-12-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57156434A (en) * 1981-03-19 1982-09-27 Takeda Chem Ind Ltd Zinc indanecarboxylate
CA2003478A1 (en) 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
US5260305A (en) 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
EP0473655B1 (en) * 1989-05-22 1997-01-15 Biochemical Veterinary Research Pty. Ltd. Divalent metal salts of indomethacin
ES2011588A6 (es) * 1989-05-29 1990-01-16 Vinas Lab Procedimiento para la preparacion de un nuevo derivado fenilacetico.
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DE69324504T2 (de) 1993-01-19 1999-08-26 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
IL162645A0 (en) * 2002-01-16 2005-11-20 Solvay Pharm Bv solid salts benzazepine compounds and their use inthe preparation of pharmaceuticals compounds
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
AU2003245736A1 (en) 2002-02-14 2003-09-04 Ranbaxy Laboratories Limited Formulations of atorvastatin stabilized with alkali metal additions
US20040034038A1 (en) 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
CN1205934C (zh) 2003-01-20 2005-06-15 鲁南制药股份有限公司 治疗高血脂症的组合物
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
AU2003269477A1 (en) * 2003-08-26 2005-03-10 Biocon Limited Novel process for preparation of 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3, 5-dihydroxy-6-heptenoic acid sodium salt
AU2004284091A1 (en) 2003-10-24 2005-05-06 Georgia State University Research Foundation, Inc Dicationic triaryl analogs as anti-protozoan agents
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
MXPA06013672A (es) 2004-05-24 2007-02-13 Warner Lambert Co Formas salinas del acido [r-(r*, r*)]-2-(4- fluorofenil)-??, d-dihidroxi-5 -(1-metiletil)-3- fenil-4 -[(fenilamino)carbonil] -1h-pirrol -1-heptanoico._.
CN1709257A (zh) * 2004-06-16 2005-12-21 鲁南制药集团股份有限公司 治疗高血脂症的组合物
EP1786414A4 (en) * 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES
CN100436428C (zh) * 2005-08-22 2008-11-26 鲁南制药集团股份有限公司 瑞舒伐他汀及其盐的制备方法
WO2009157014A2 (en) 2008-01-30 2009-12-30 Cadila Healthcare Limited A process for preparing hmg-coa reductase inhibitors and intermediates
BRPI1005147A2 (pt) * 2009-01-15 2019-09-24 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag processo de preparação de sais de rosuvastatina
HU230987B1 (hu) * 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására

Also Published As

Publication number Publication date
CA2649219A1 (en) 2007-10-25
JP2009533412A (ja) 2009-09-17
CN101490015B (zh) 2013-06-12
HUP0600293A3 (en) 2008-04-28
CN101490015A (zh) 2009-07-22
EA200802142A1 (ru) 2009-02-27
US9174945B2 (en) 2015-11-03
EP2013188B1 (en) 2016-09-07
KR20080109088A (ko) 2008-12-16
CA2649219C (en) 2014-12-23
ES2605579T3 (es) 2017-03-15
JP5439168B2 (ja) 2014-03-12
EP2013188A1 (en) 2009-01-14
WO2007119085A1 (en) 2007-10-25
EA016141B1 (ru) 2012-02-28
US20090306117A1 (en) 2009-12-10
HUP0600293A2 (en) 2007-12-28
IL194674A (en) 2013-10-31
HU227696B1 (en) 2011-12-28
HU0600293D0 (en) 2006-05-29

Similar Documents

Publication Publication Date Title
UA95287C2 (en) Rosuvastatin zinc salt
MX363983B (es) Compuestos de enaminocarbonilo sustituidos.
TW200833682A (en) Pharmaceutical compounds
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
MX2009008781A (es) Derivados de ciclohexano espirociclicos.
GB0719180D0 (en) New process
TN2011000053A1 (en) Organic compounds
AU2008235089A8 (en) Insecticidal aryl isoxazoline derivatives
WO2008110281A3 (de) 3,4-disubstituierte phenoxyphenylamidine und deren verwendung als fungizide
MX358961B (es) Compuestos de tetraciclina sustituidos con fluor en c7.
AU2015221439B2 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
MX2009010046A (es) Composicion agricola para controlar o prevenir enfermedades de plantas causadas por microbios patogenos de las plantas.
MX2013000295A (es) Procedimiento de preparacion de un inhibidor especifico de la trombina.
WO2014054058A8 (en) Novel compounds, their synthesis and their uses
IN2012DN02502A (ru)
MX2009008772A (es) Derivado piridil-triazolopirimidina o su sal, pesticida que lo contiene y proceso para su produccion.
MX2011011776A (es) Nuevos profarmacos de triptolite.
PL1902036T3 (pl) Sposób wytwarzania rosuwastatyny i związki pośrednie
TW200612959A (en) Method for preparing hydroxamic acids
PT1745010E (pt) Derivados de ciclo-hexil-1,4-diamina substituídos
WO2010132670A3 (en) Pentacycline compounds
NZ593102A (en) Dihydroetorphines and their preparation
MX2011011025A (es) Preparacion de c-piracin-metilaminas.
UA93860C2 (ru) Способ получения пиразолов, способ региоселективного алкилирования и применение фосфата или фосфоната b способе
SG10201406839VA (en) Benzazepine compound